Fairgrounds becoming running Mecca for races, fundraisers
What started with a call out of the blue last year has turned into a six-figure revenue stream for the Indiana State Fairgrounds. And that revenue stream could get a lot bigger.
What started with a call out of the blue last year has turned into a six-figure revenue stream for the Indiana State Fairgrounds. And that revenue stream could get a lot bigger.
The federal government is set to decide this month whether the federal Medicare program should pay for a $3,000 test that for the first time accurately identifies the signature brain plaques of Alzheimer’s disease, according to Bloomberg News. The test, approved last year by U.S. regulators, uses Eli Lilly and Co.’s Amyvid imaging agent to trace the brain protein amyloid. Alzheimer’s disease affects 5 million Americans, a number that patient advocates say could double by 2050. But the test is controversial because there are no available treatments that even slow the progression of Alzheimer’s disease. A final decision from the federal Centers for Medicare & Medicaid Services will come July 9. While a negative decision would limit use of the tests, approval would probably lead to coverage from private health insurers, too.
Nyhart Actuary & Employee Benefits plans to expand its Indianapolis headquarters and create as many as 25 jobs here by 2017. The firm will invest $840,000 to lease and equip an additional 8,000 square feet of office space, according to Nyhart CEO Thomas Toten. Nyhart currently is negotiating an expansion of the 20,000 square feet it leases at 8415 Allison Pointe Blvd. in the Castleton area. Nyhart currently has 68 full-time employees in Indianapolis and about another 30 across five other states. The firm already has started hiring additional actuaries, administrators and benefit consultants from college programs for its Indianapolis expansion. Founded in 1943, Nyhart provides consulting services to more than 1,000 public and private companies in 48 states on issues such as pensions, retirement benefits, compensation and other employee benefits. Nyhart has been in growth mode lately. In August, Nyhart acquired San Diego-based The Epler Co., a regional actuarial, employee benefits and compensation strategies firm.
Lilly Endowment Inc. will give $10 million to help start the Indiana Biosciences Institute. The institute is already due to receive $25 million in startup funds from the state. The institute aims to attract 100 new scientists to Indiana to conduct research and development work aimed at launching new therapies for metabolic diseases. The effort has been spearheaded by BioCrossroads, an Indianapolis-based life sciences organization, and has received significant support from Gov. Mike Pence and John Lechleiter, the CEO of Eli Lilly and Co. The institute needs to raise $15 million over the next year or so to fully fund its startup efforts. Beyond that, the institute hopes to raise an endowment of $310 million to help fund its operations. It also hopes its researchers attract steady grants from life sciences research companies, such as Indianapolis-based Lilly and Bloomington-based Cook Group Inc.
Eli Lilly and Co. won a United Kingdom patent lawsuit against a Johnson & Johnson unit over a potential treatment for Alzheimer’s disease, according to Bloomberg News. A patent held by J&J’s Janssen Alzheimer Immunotherapy Research & Development unit isn’t valid, Judge Richard Arnold said in a ruling in London on June 25. Both companies are developing treatments targeting the buildup of plaque in patients’ brains that’s linked to the condition. Companies developing the first treatments for Alzheimer’s are competing for what might be a $20 billion market, according to a report last year by Deutsche Bank AG analysts.
The head of the state Family and Social Services Administration said the federal government is expected to approve an extension of the Healthy Indiana Plan, but a request to use the plan for an Indiana Medicaid expansion could take much longer. According to the Associated Press, FSSA Secretary Debra Minott said Gov. Mike Pence directed her and others to ensure those already enrolled in HIP are secure before negotiating an expansion through the program. Roughly 40,000 low-income residents are enrolled in the program, which operates under a federal waiver. But the waiver is set to expire at the end of the year, potentially leaving enrollees without coverage. Pence resubmitted an application with the Centers for Medicare and Medicaid Services in April seeking to use the state's hybrid health savings account plan as the vehicle for Medicaid expansion. CMS rejected an earlier request from former Gov. Mitch Daniels, citing concerns about the premium paid by members and a need for improved coverage. The expansion would cover residents earning up to 138 percent of the federal poverty level, using new funds authorized by Obamacare.
Having two players selected in the top four of last week's NBA draft will only bolster IU Coach Tom Crean's recruiting efforts. But some IU alums are asking how a team with two such players got knocked out of the Sweet Sixteen.
Frank Sinatra and Jimmy Webb also honored as inductees into Michael Feinstein’s Great American Songbook Hall of Fame.
Dozens of new rules and regulations have been implemented in Indiana in recent months despite an executive order Gov. Mike Pence signed on his first day in office.
Successful professionals that double as weekend race warriors and gear heads are drawn to a racetrack and club on the edge of the middle of nowhere by their love of cars and need for speed.
Over the last quarter century, the husband-wife duo has outlived a number of bigger and slicker competitors, even as the Great Recession decimated some bigger PR and advertising shops.
Indianapolis Motor Speedway officials say they’ve seen no adverse sales impact from a risky move to raise ticket prices for the 2014 Indianapolis 500 by about 15 percent—the first price increase in almost a decade.
Evansville-based Old National Corp. will pay Gov. Mitch Daniels’ sidekick Becky Skillman $70,000 a year in a combination of cash and stock to serve as a director.
Forefront gives you a wide range of opinions in a tidy package.
The Star sports department is undergoing a major shakeup, including reassignments for some of the paper’s most tenured beat writers—covering the Indiana Pacers, Indianapolis Colts, IU and Butler.
Doubling up this week with stuff to do for this week and next (Yes, I’m taking the 4th of July off).
Everyone knows the old real estate adage about location, location, location. But these days, for revenue-hungry Indianapolis communities, you can add another priority—development, development, development.
Three promising efforts are under way in Indianapolis to unite the community and propel us forward. I hope we pursue each initiative with a sense of urgency and change the trajectory on our health, skills and economic prosperity.
More than 500 of the country’s best swimmers will be in Indianapolis this week to compete in the Phillips 66 National Swimming Championships in the IU Natatorium at IUPUI. The event, which runs Tuesday through Saturday, is a qualifier for the world championships next month in Spain. About 20 Olympians, including Ryan Lochte, will appear at a Fan Expo during the event.
Hostess Brands LLC has asked the city for a tax abatement on $10 million in new equipment. City officials might decide on July 3, but Hostess is moving ahead with its plans to reopen the plant that closed in November.
An eastern Indiana city could sell the factory to a cabinet company for $1 as part of a deal for it to hire more than 300 workers.
It looks like Eli Lilly and Co. has a winner. The Indianpaolis-based drugmaker’s experimental diabetes drug dulaglutide helped patients with Type 2 diabetes lose weight while suffering only manageable side effects, according to Phase 3 clinical trial data released over the weekend at the American Diabetes Association meeting in Chicago. According to Bloomberg News, dulaglutide, if approved, may be a significant competitor to Novo Nordisk A/S’ Victoza, which generated $1.64 billion in 2012. A clinical trial comparing the drugs may report results by the end of the year. “We look at the space and we feel we have an opportunity to offer a significant new product,” said Sherry Martin, senior medical director for diabetes development at Indianapolis-based Lilly. The company plans to submit the drug to U.S. regulators for approval by the end of this year. Dulaglutide is projected to sell $835 million in 2018, according to the average of six analysts’ estimates compiled by Bloomberg. Martin said the drug would be the only weekly injection in the class that doesn’t require patients to prepare the dose for administration.
The California Public Employees Retirement System saved $5.5 million, or 19 percent of its affected medical claims, under a two-year pilot project with Indianapolis-based WellPoint Inc. that steered patients away from high-cost health care providers that don’t produce better outcomes. WellPoint executives told Bloomberg News that the cost-capping, or reference-pricing, policy employed in the pilot program is now gaining momentum among employers. The California pension program, known as Calpers, became a partner in the pilot program after a WellPoint analysis found similar hip and knee surgeries cost anywhere from $15,000 to $110,000 per patient, with no difference in patient outcomes, according to Bloomberg. So in 2011, Calpers and WellPoint’s Anthem Blue Cross unit began steering patients toward 46 hospitals that agreed to keep their costs below $30,000—known as the program's “reference price.” If workers went to another provider, then they were responsible for any costs above $30,000. About 400 members opted for the designated hospitals in 2011, a 21-percent increase over previous years. Calpers’ in-patient costs for hip and knee surgeries dropped to an average of $28,695 from $35,400, according to WellPoint. The study was conducted by HealthCore, a research unit owned by WellPoint, and released Sunday at the AcademyHealth Annual Research Meeting in Baltimore.
Researchers at the Indiana University School of Medicine blocked the progression of Type 1 diabetes among newly diagnosed patients using a drug originally sold to treat psoriasis. In a clinical trial involving 49 patients, those who were given the drug alefacept (sold under the brand name Amevive) kept producing the same amount of insulin over the next year, while patients receiving a placebo saw their level of insulin drop over the same period. If the results are repeated in studies involving more patients, the drug could enable Type 1 diabetics to maintain some insulin production and avoid the debilitating complications caused by the disease, said Dr. Mark R. Rigby, a professor of pediatrics at the IU medical school. Nearly 3 million people are estimated to have Type 1 diabetes in the United States. Although the disease can be managed with insulin injections, it cannot be reversed or cured. Long-term complications can include visual impairment, heart disease, stroke, problems in the extremities leading to amputation, and other problems.
An Indiana University School of Medicine researcher has received a $3.8 million three-year grant from the National Institutes of Health to study estrogen as a treatment for schizophrenia using an unreleased drug developed by Eli Lilly and Co. A team led by Dr. Alan Breier, a professor of psychiatry at the IU medical school, will use a drug discovered by Lilly scientists that mimics some of the actions of the hormone estrogen, but without many of the side effects, such as feminization in men and uterine cancer in women. Breier's study is one of nine projects to receive support from a new NIH program called Discovering New Therapeutic Uses for Existing Molecules.
With recent attention focused on hospital prices, WellPoint and its peers have been enjoying a nice break from their long-running status as Public Enemy No. 1 in the nation’s health care debate. They shouldn’t expect it to last.